伦敦的 Otton’s 等餐厅正把“奢华大份量”改成“精致小口”，例如推出小份煎小牛肉；伯克郡拥有三枚米其林星的 Fat Duck 提供“Mindful Experience”，而 The Banc（伦敦与迪拜）和纽约的 Renwick Hospitality Group 也分别上了迷你菜单与零食份量选项。共同点是：为了适应使用减重药物、进食更少的顾客而缩小份量。

GLP-1 类药物（如 Ozempic、Wegovy、Mounjaro）通过模拟“饱腹激素”来抑制食欲，2024 年全球相关支出约 540 亿美元，并预计将继续上升。盖洛普数据显示约八分之一的美国成年人曾为减重使用 GLP-1；KAM 估计英国成年人使用者占 4% 到 7%，与素食者（5%）或食物过敏者（6%）的比例相近。

目前多数 GLP-1 使用者来自中高收入家庭；在英国，58% 通过自费获得，32% 通过 NHS 获得，10% 通过其他方式获得，而 KAM 发现 57% 的使用者计划只在特殊场合去餐厅。尽管吃得更少，他们仍愿意为“犒赏”买单，且小份菜可以按比例收取更高价格；随着药价可能下降、更多美国人可负担，纽约等地休闲餐饮已推出迷你套餐与专门菜单。

Restaurants such as Otto’s in London are shifting “luxury in large portions” into “luxury in small bites,” such as smaller pan-fried veal; the three-Michelin-star Fat Duck in Berkshire offers a “Mindful Experience,” and The Banc (London and Dubai) plus New York’s Renwick Hospitality Group have added mini menus and snack-size options. The common driver is adapting to customers on weight-loss medication who expect to eat less.

GLP-1 drugs (such as Ozempic, Wegovy and Mounjaro) mimic a fullness hormone to suppress appetite, with global spending reaching about $54bn in 2024 and expected to keep rising. Gallup reports about one in eight American adults has taken a GLP-1 drug for weight loss; KAM estimates 4% to 7% of British adults are users, similar to vegetarians (5%) or those with food allergies (6%).

Most GLP-1 users currently come from middle- or high-income households; in Britain, 58% obtain the medication privately, 32% via the NHS and 10% in other ways, and KAM finds 57% of users plan to visit restaurants only for special occasions. Even if they want less food, they still pay for treats, and smaller plates can support proportionately higher pricing; as drug prices may fall and access widens in America, casual operators are already rolling out mini meals and GLP-1-themed menus.

Source: Restaurants are changing their menus for the age of Ozempic

Subtitle: The challenge is enticing those with reduced appetites to dine out

Dateline: 12月 30, 2025 05:48 上午